180 related articles for article (PubMed ID: 30947657)
21. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
Huang S; Qing C; Huang Z; Zhu Y
Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
24. Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer.
Fu LL; Li CJ; Xu Y; Li LY; Zhou X; Li DD; Chen SX; Wang FG; Zhang XY; Zheng LW
Crit Rev Eukaryot Gene Expr; 2017; 27(2):183-195. PubMed ID: 28845767
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNAs: A view to kill ovarian cancer.
Zamaraev AV; Volik PI; Sukhikh GT; Kopeina GS; Zhivotovsky B
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188584. PubMed ID: 34157315
[TBL] [Abstract][Full Text] [Related]
26. Progress of long noncoding RNAs in anti-tumor resistance.
Zhang H; Wang Y; Liu X; Li Y
Pathol Res Pract; 2020 Nov; 216(11):153215. PubMed ID: 32979688
[TBL] [Abstract][Full Text] [Related]
27. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
Özeş AR; Miller DF; Özeş ON; Fang F; Liu Y; Matei D; Huang T; Nephew KP
Oncogene; 2016 Oct; 35(41):5350-5361. PubMed ID: 27041570
[TBL] [Abstract][Full Text] [Related]
28. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting.
Singh D; Khan MA; Siddique HR
Mol Biol Rep; 2020 Jul; 47(7):5569-5585. PubMed ID: 32601922
[TBL] [Abstract][Full Text] [Related]
29. Interaction between LncRNA-ROR and miR-145 contributes to epithelial-mesenchymal transition of ovarian cancer cells.
Li J; Zhang S; Wu L; Pei M
Gen Physiol Biophys; 2019 Nov; 38(6):461-471. PubMed ID: 31829305
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer.
Peng Y; Tang D; Zhao M; Kajiyama H; Kikkawa F; Kondo Y
Cancer Metastasis Rev; 2020 Sep; 39(3):825-835. PubMed ID: 32594276
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells.
Yan H; Xia JY; Feng FZ
Genet Mol Res; 2017 Jan; 16(1):. PubMed ID: 28128423
[TBL] [Abstract][Full Text] [Related]
32. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
[No Abstract] [Full Text] [Related]
33. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
34. Non-coding RNA in drug resistance of hepatocellular carcinoma.
Ding B; Lou W; Xu L; Fan W
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30224380
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients.
Zhou M; Zhong L; Xu W; Sun Y; Zhang Z; Zhao H; Yang L; Sun J
Sci Rep; 2016 Aug; 6():31038. PubMed ID: 27503456
[TBL] [Abstract][Full Text] [Related]
36. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
37. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells.
Vera O; Rodriguez-Antolin C; de Castro J; Karreth FA; Sellers TA; Ibanez de Caceres I
Epigenetics; 2018; 13(3):251-263. PubMed ID: 29436261
[TBL] [Abstract][Full Text] [Related]
38. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high‑grade ovarian serous cancer.
Lou Y; Jiang H; Cui Z; Wang X; Wang L; Han Y
Int J Mol Med; 2018 Jul; 42(1):91-104. PubMed ID: 29577163
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
[TBL] [Abstract][Full Text] [Related]
40. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
